Načítá se...
Cost burden of diffuse large B-cell lymphoma
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogenous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. AREAS COVERED: We review the cost burden of DLBCL and cost-effectiveness of DL...
Uloženo v:
| Vydáno v: | Expert Rev Pharmacoecon Outcomes Res |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6930962/ https://ncbi.nlm.nih.gov/pubmed/31623476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737167.2019.1680288 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|